99% Purity Raw Powder Lanreotide CAS 108736-35-2 Lanreotide Powder Lanreotide

• Customization: Available
• CAS No.: 108736-35-2
• Formula: C54h69n11o10s2
• Model NO.: Dsung-Lanreotide
• EINECS: 1592732-453-0
• Type: Pharmaceutical Intermediates
• Appearance: Powder
• Quality: Pharmaceutical Grade
• Colour: White
• Product Name: Lanreotide
• MW: 1096.333
• Name: Lanreotide Powder
• Color: White
• Grade: Pharmaceutical Grade
• Application: Pharmaceutical
• Certificate: ISO, GMP
• Specfic: COA
• Test Method: HPLC
• Boiling Point: 1508.2 Cat760mmhg
• Refractive Index: 1.689
• Density: 1.323 g/cm3
• Shelf Life: 2 Years
• Torage Temperature: Keep Dark and Dry Place
• English Alias: Angiopeptin
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 500kg/Month

Product Description

99% Purity Raw Powder Lanreotide CAS 108736-35-2 Lanreotide Powder Lanreotid

Product Description

Product Details

Product Name	Lanreotide
Color	White
Shelf Life	2Years
Sample	Available
Test Method	HPLC,UV

Lanreotide (INN) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin, like octreotide. Its sequence is H-D-2Nal-Cys(1)-Tyr-D-Trp-Lys-Val-Cys(1)-Thr-NH2.
Lanreotide (as lanreotide acetate) is manufactured by Ipsen, and marketed under the trade name Somatuline. It is available in several countries, including the United Kingdom, Australia and Canada, and was approved for sale in the United States by the Food and Drug Administration (FDA) .
Lanreotide is a synthetic analogue of somatostatin, a naturally occurring inhibitory hormone which blocks the release of several other hormones,thyroid-stimulating hormone (TSH). Lanreotide binds to the same receptors as somatostatin, although with higher affinity to peripheral receptors, and has similar activity. However, while somatostatin is quickly broken down in the body (within minutes), lanreotide has a much longer half-life, and produces far more prolonged effects.

Application & Function

Lanreotide is used in the treatment of acromegaly, due to both pituitary and non-pituitary the management of symptoms caused by neuroendocrine tumors, particularly carcinoid tumors and VIPomas. In the United States and Canada, lanreotide is only indicated for the treatment of acromegaly. In the United Kingdom, it is also indicated in the treatment of thyrotrophic adenoma,a rare tumor of the pituitary gland which secretes TSH.
Lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogues, is being studied as a possible general antitumor agent.
In Dec 2014 the US FDA approved lanreotide for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
It is used for polycystic liver disease. It has also been shown that it reduces the volume by 264mls on average.

Specification